Prescription medicine
Thyroid
Thyroid is a prescription medicine. No generic is listed; pharmacies paid $1.20 per thyroid 120 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the thyroid FDA label on DailyMed (effective November 15, 2023); every thyroid label on DailyMed.
Highlights of the record
FDA label of November 15, 2023; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageSymptoms of eczema or psoriasis*
Forms and strengths
- 15 mg
- 30 mg
- 60 mg
- 90 mg
- 120 mg
- 180 mg
- 240 mg
- 300 mg
Tablet.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 7 of which 0 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $1.20 per tablet Thyroid 120 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 5 since 2013 1 Class I among all firms' recalls; latest January 16, 2026; 7 more by firms not listed as its makers
- FAERS reports
- 2,855 through July 30, 2026
What is thyroid used for?
From the label: indications and usageSymptoms of eczema or psoriasis*
Source: FDA drug label (Thyroidinum), Boiron, effective November 15, 2023 (SPL set 86335e4b-a2f8-6143-e053-2a91aa0a29c6), via openFDA; the full label on DailyMed
Is there a generic for thyroid?
No generic thyroid is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for thyroid?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $1.20 per Thyroid 120 mg tablet, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Thyroid 15 mg tablet (generic)
- Armour thyroid 15 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Amerithroid 120 mg tablet | Generic | $1.20 per tablet | $35.93 | n/a |
| Amerithroid 15 mg tablet | Generic | $0.525 per tablet | $15.74 | n/a |
| Amerithroid 30 mg tablet | Generic | $0.592 per tablet | $17.75 | n/a |
| Amerithroid 60 mg tablet | Generic | $0.671 per tablet | $20.13 | n/a |
| Amerithroid 90 mg tablet | Generic | $1.01 per tablet | $30.17 | n/a |
| Niva thyroid 120 mg tablet | Generic | $1.20 per tablet | $35.93 | +0.2% |
| Niva thyroid 15 mg tablet | Generic | $0.525 per tablet | $15.74 | +1% |
| Niva thyroid 30 mg tablet | Generic | $0.592 per tablet | $17.75 | +1% |
| Niva thyroid 60 mg tablet | Generic | $0.671 per tablet | $20.13 | +0.2% |
| Niva thyroid 90 mg tablet | Generic | $1.01 per tablet | $30.17 | -3% |
| Thyroid 120 mg tablet | Generic | $1.20 per tablet | $35.93 | +0.2% |
| Thyroid 15 mg tablet | Generic | $0.525 per tablet | $15.74 | +1% |
| Thyroid 30 mg tablet | Generic | $0.592 per tablet | $17.75 | +1% |
| Thyroid 60 mg tablet | Generic | $0.671 per tablet | $20.13 | +0.2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has thyroid been recalled?
The FDA's Enforcement Report lists 12 recalls naming thyroid since 2013: 1 Class I (the most serious), 11 Class II, 0 Class III; 2 still ongoing. 7 of them are by firms that FDA's NDC Directory does not list as a maker of thyroid and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| August 21, 2026 | Class I | VITRUVIAS THERAPEUTICS INC not a listed maker | Superpotent Drug |
| January 16, 2026 | Class II | Specialty Process Labs LLC | Subpotent Drug |
| January 26, 2022 | Class II | CARDINAL HEALTHCARE not a listed maker | CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. |
| August 30, 2018 | Class II | Alkano Chemicals, Inc | CGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine. |
| August 28, 2018 | Class II | Humco Holding Group, Inc | CGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine. |
| August 24, 2018 | Class II | LGM Pharma LLC not a listed maker | CGMP Deviations: Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine. |
| August 22, 2018 | Class II | Syntec Pharma Corp not a listed maker | CGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine. |
| July 2, 2013 | Class II | Aidapak Services, LLC not a listed maker | Labeling: Label Mixup: THYROID, Tablet, 30 mg may have potentially been mislabeled as one of the following drugs: OMEPRAZOLE/SODIUM BICARBONATE, Capsule, 20 … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the thyroid label say about other medicines?
The thyroid label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Cholestyramine | drug interactions (prescription label) | Therefore four to five hours should elapse between administration of cholestyramine and thyroid hormones. |
| Levothyroxine | drug interactions (prescription label) | In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements. |
Source: FDA drug label (Thyroidinum), Boiron, effective November 15, 2023 (SPL set 86335e4b-a2f8-6143-e053-2a91aa0a29c6), via openFDA; the full label on DailyMed
What do FAERS reports show for thyroid?
The FDA Adverse Event Reporting System holds 2,855 reports that list thyroid among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 121 are coded as a death and 504 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Thyroid side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other